Yuhan Joins Immuno-Oncology Wave Via Sorrento JV
This article was originally published in PharmAsia News
One of South Korea's leading pharma firms, Yuhan, is joining the global immuno-oncology wave by setting up a majority-owned joint venture with US-based Sorrento Therapeutics. The JV, Yuhan’s first in R&D, is set to develop and commercialize three of Sorrento's immune checkpoint antibodies.
Register for our free email digests: